While the company has yet to disclose the size of the offering or the anticipated price per share, it has confirmed that Morgan Stanley, Leerink Partners, and Citigroup are serving as underwriters. The agreement includes a 30-day option for these banks to purchase additional units to cover potential over-allotments.

Attovia focuses on treatments for immune-mediated diseases, supported by backers including Deep Track Capital, Frazier Life Sciences, and Goldman Sachs Alternatives. The firm raised $90 million during a 2025 Series C round, capital that fueled its current pipeline. Proceeds from the upcoming IPO are earmarked for the advancement of research and the clinical evaluation of ATTO-1310, a candidate aimed at chronic pruritic conditions.